- Home
- PRT vs SNTI Comparison
PRT vs SNTI Comparison
Compare PRT & SNTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRT
- SNTI
- Stock Information
- Founded
- PRT 2017
- SNTI 2016
- Country
- PRT United States
- SNTI United States
- Employees
- PRT N/A
- SNTI N/A
- Industry
- PRT Oil & Gas Production
- SNTI Biotechnology: Pharmaceutical Preparations
- Sector
- PRT Energy
- SNTI Health Care
- Exchange
- PRT Nasdaq
- SNTI Nasdaq
- Market Cap
- PRT 48.1M
- SNTI 39.6M
- IPO Year
- PRT N/A
- SNTI N/A
- Fundamental
- Price
- PRT $3.88
- SNTI $2.16
- Analyst Decision
- PRT
- SNTI Strong Buy
- Analyst Count
- PRT 0
- SNTI 3
- Target Price
- PRT N/A
- SNTI $9.67
- AVG Volume (30 Days)
- PRT 32.2K
- SNTI 330.2K
- Earning Date
- PRT 11-12-2025
- SNTI 11-13-2025
- Dividend Yield
- PRT 10.78%
- SNTI N/A
- EPS Growth
- PRT 1.16
- SNTI N/A
- EPS
- PRT 0.44
- SNTI N/A
- Revenue
- PRT $6,314,770.00
- SNTI N/A
- Revenue This Year
- PRT N/A
- SNTI N/A
- Revenue Next Year
- PRT N/A
- SNTI $150.00
- P/E Ratio
- PRT $8.88
- SNTI N/A
- Revenue Growth
- PRT 1.82
- SNTI N/A
- 52 Week Low
- PRT $3.26
- SNTI $1.26
- 52 Week High
- PRT $4.63
- SNTI $16.94
- Technical
- Relative Strength Index (RSI)
- PRT 45.00
- SNTI 67.20
- Support Level
- PRT $3.88
- SNTI $2.07
- Resistance Level
- PRT $3.99
- SNTI $2.55
- Average True Range (ATR)
- PRT 0.06
- SNTI 0.24
- MACD
- PRT -0.00
- SNTI 0.06
- Stochastic Oscillator
- PRT 20.55
- SNTI 62.61
About PRT PermRock Royalty Trust Trust Units
PermRock Royalty Trust operates as a statutory trust. Its purpose is to own the Net Profits Interest, to distribute to the Trust unitholders cash that it receives in respect of the Net Profits Interest, and to perform certain administrative functions. The Net Profits Interest entitles the trust to receive the net profits from the sale of oil and natural gas production from the underlying properties of its trustor.
About SNTI Senti Biosciences Inc.
Senti Biosciences Inc is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma.